BioLineRx (BLRX)
(Delayed Data from NSDQ)
$0.78 USD
0.00 (0.49%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $0.79 +0.02 (1.94%) 6:10 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
BioLineRx Ltd. [BLRX]
Reports for Purchase
Showing records 41 - 60 ( 205 total )
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Early Look at Phase 3 Lead-In Points to Getting Cells to Patients Faster
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
AGI-134 Hits the Clinic as Expected; Dual-Pronged Mechanism Should Yield Intriguing Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Study Expanding to Explore Third ''Punch''; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
New Biomarker Directly Correlates With BL-8040 AML Induced Survival; Plethora of Upcoming Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
1Q18 Results; Prepping for Multiple Data Catalysts
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
2017 Results; Investors Should Be Prepped Ahead of Several 2H18 Data Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Looks Like ''8040 Is Opening the Door; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
The GENESIS of Company''s First Pivotal Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Brewing Excitement for 2018; Investor Day Recap; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
AML Needle Continues to Point in Right Direction; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
3Q17 Results; Looking Toward a Busy Data Year in 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Genentech Collaboration Continues to Expand as Expected; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
BL-8040 and Tecentriq Ready to BATTLE AML as Programs Expand
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
2Q17 Results; The Password Is: BL-8040; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
2Q17 Results; The Password Is: BL-8040; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Genentech Officially Presses Play; Meaningful Answers to Come; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Genentech Officially Presses Play; Meaningful Answers to Come; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
1Q17 Results; All Eyes on ''8040 Collaborations and Pivotal Plans
Provider: Rodman & Renshaw, Co.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
1Q17 Results; All Eyes on ''8040 Collaborations and Pivotal Plans
Provider: H.C. Wainwright & Co., Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Corrected - Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.